Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.
You may also be interested in...
Leo Pharma Gets Patient-Centric On The Frontiers Of Psoriasis
Denmark’s dermatology specialist Leo Pharma has linked up with a U.S. psoriasis patient group, the National Psoriasis Foundation, to target innovation on unmet clinical needs.
Deals Of The Week: Sanofi/Genfar, Janssen/Astellas, Evotec/Bayer
It was an important week for Celgene, which made two cancer deals while producing data that help validate its $2.9 billion buyout of Abraxane.
Denmark’s Leo Pharma Forms Collaboration With Berlin’s Charité University Hospitals
Denmark’s dermatology-focused Leo Pharma sets up the first of a series of long-term collaborations with clinical researchers to boost its R&D pipeline.